4 news items
Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?
HEPA
22 Apr 24
with the first patient screened in August 2022 to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AAOI
AGBA
AGRI
22 Apr 24
and raised its price target from $62 to $70.
Ingevity Corporation
Hepion Pharmaceuticals Initiates Wind-Down Activities In Phase 2b 'ASCEND-NASH' Trial
HEPA
19 Apr 24
screened in August 2022, to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enrollment
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial
HEPA
19 Apr 24
-blinded study with first patient screened in August 2022, to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target
- Prev
- 1
- Next